Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty

Next Previous
X
Search
Trial Profile

A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isomyosamine (Primary)
  • Indications Inflammation; Sarcopenia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors MyMD Pharmaceuticals; TNF Pharmaceuticals

    • Most Recent Events

    • 22 Jul 2024 According to TNF Pharmaceuticals media release, MyMD Pharmaceuticals, Inc changed its name to TNF Pharmaceuticals, Inc.
    • 21 May 2024 According to a MyMD Pharmaceuticals media release, company announced positive data and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FDA).
    • 04 Oct 2023 According to a MyMD Pharmaceuticals media release, the company will present data from this study at the upcoming BioFuture 2023 Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top